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Abstract
Background: In addition to cervical cancer, human papillomavirus (HPV) is responsible for a significant proportion of
cancers and precancerous lesions of the vulva, vagina, anus, penis, head and neck, as well as genital warts. We estimated the
annual number of new cases of these diseases attributable to 9-valent HPV vaccine types in women and men in Europe.
Methods: The annual number of new cancers of the cervix, vulva, vagina, anus, penis, and selected head and neck sites in
the population of the European Medicines Agency territory was estimated based on age-specific incidence rates extracted
from Cancer Incidence in 5 Continents, Volume X and Eurostat population data for 2015. The annual number of
new cancers attributable to 9-valent HPV vaccine types was estimated by applying the HPV attributable fraction
from reference publications based on a large European multicenter study. For non-cervical cancers, HPV
attributable fractions were based on oncogenically-active HPV infections only (i.e., detection of HPV DNA and
either mRNA and/or p16 positivity). For precancerous lesions of the cervix, vulva, vagina, and anus, and for genital
warts, previously published estimations were updated for the 2015 population.
Results: The annual number of new cancers attributable to 9-valent HPV vaccine types was estimated at 47,992
(95% bound: 39,785-58,511). Cervical cancer showed the highest burden (31,130 cases), followed by head and
neck cancer (6,786 cases), anal cancer (6,137 cases), vulvar cancer (1,466 cases), vaginal cancer (1,360 cases), and
penile cancer (1,113 cases). About 81% were estimated to occur in women and 19% in men. The annual number
of new precancerous lesions (CIN2+, VIN2/3, VaIN2/3, and AIN2/3) and genital warts attributable to 9-valent HPV
vaccine types was estimated at 232,103 to 442,347 and 680,344 to 844,391, respectively.
Conclusions: The burden of cancers associated with 9-valent HPV vaccine types in Europe is substantial in both
sexes. Head and neck cancers constitute a heavy burden, particularly in men. Overall, about 90% of HPV-related
cancers, 80% of precancerous lesions, and 90% of genital warts are expected to be attributable to 9-valent HPV
vaccine types each year, demonstrating the important preventive potential of the 9-valent HPV vaccine in Europe.
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Background
Human papillomavirus (HPV) infections are the most
common sexually transmitted infections, with more than
40 HPV types that can be transmitted through direct sex-
ual contact, of which about a dozen are classified as high-
risk types. Persistent infection with high-risk HPV types
can cause cellular changes that may progress to cancer or
precancerous lesions of the cervix, vagina, vulva, anus,
penis, and head and neck. On the other hand, low-risk
types can cause genital warts and recurrent respiratory
papillomatosis (RRP), but cause cancer very rarely [1].
Indeed, the high-risk HPV types 16, 18, 31, 33, 45, 52, and
58 are responsible for about 90% of cervical cancers world-
wide, whereas HPV6 and 11 are low-risk types for cancer
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but are responsible for about 90% of warts on or around
the genitals, anus, mouth, and throat (RRP) [2].
The quadrivalent HPV vaccine, Gardasil®/Silgard®
(Sanofi Pasteur MSD/Merck Sharp & Dohme), protects
against infection with HPV16, 18, 6, and 11, and was li-
censed in Europe in 2006. It was followed in 2007 by the
bivalent HPV vaccine, Cervarix® (GlaxoSmithKline Bio-
logicals), which protects against infection with HPV16
and 18. Both vaccines have reassuring safety profiles, as
demonstrated in clinical trials and several large post-
licensure studies [3], and they provide a high level of
protection against HPV16- and 18-attributable lesions.
In 2015, the 9-valent HPV vaccine, Gardasil9 (Sanofi
Pasteur MSD/Merck Sharp & Dohme), was licensed in
Europe for the prevention of cancers and precancerous
lesions of the cervix, vulva, vagina, and anus, as well as
genital warts caused by HPV6, 11, 16, 18, 31, 33, 45, 52,
and 58 [4]. This vaccine protects against five high-risk
HPV types not included in first-generation HPV vaccines
(HPV31, 33, 45, 52, and 58) [1].
We recently published an estimation of the annual bur-
den of cancers and precancerous lesions of the cervix,
vulva, vagina, and anus, and of genital warts attributable
to 9-valent HPV vaccine types in Europe in 2013, and
compared it to the estimated annual burden of the same
lesions attributable to quadrivalent HPV vaccine types [5].
Recently, two new papers [6, 7] based on a large European
multicenter study have published information on HPV
type distribution and HPV attributable fractions in head
and neck and penile cancers, which gave us the oppor-
tunity to provide robust estimates on the contribution
of 9-valent HPV vaccine types at these sites as well.
Therefore, in order to provide a more exhaustive over-
view of the preventive potential of the 9-valent HPV
vaccine, we have updated our previous estimates to
2015. These new estimates include the annual number
of new cancers of the cervix, vulva, vagina, anus, penis,
and head and neck; the annual number of new precan-
cerous lesions of the cervix, vulva, vagina, and anus;
and the annual number of genital warts cases attributable
to 9-valent HPV vaccine types, including the low-risk
types HPV6 and 11, in Europe in 2015.
Methods
Estimation of the annual number of new HPV-related
cancers in Europe
The present evaluation was based on cancer incidence
data from Cancer Incidence in Five Continents (CI5)
Volume X, which were collected from 2003 through
2007. The CI5 database is available on the website of the
International Agency for Research on Cancer (IARC) [8]
and contains worldwide data on cancer incidence rates
classified by International Classification of Diseases 10th
Revision (ICD-10) codes. These data are obtained from
regional or national registries, depending on the country,
but to be included in CI5 these registries must meet the
IARC’s quality criteria, i.e., they must have reliable can-
cer registry data. We compiled data on 32 countries: 31
countries covered by the European Medicines Agency
(EMA, Austria, Belgium, Bulgaria, Croatia, Cyprus, the
Czech Republic, Denmark, Estonia, Finland, France,
Germany, Greece, Hungary, Iceland, Ireland, Italy,
Latvia, Liechtenstein, Lithuania, Luxemburg, Malta, the
Netherlands, Norway, Poland, Portugal, Romania,
Slovenia, Slovakia, Spain, Sweden, and the United King-
dom) and one not covered by the EMA (Switzerland).
The information in CI5 Volume X was obtained from
national cancer registries for Belgium, Bulgaria, Croatia,
Cyprus, the Czech Republic, Denmark, Estonia, Finland,
Iceland, Ireland, Latvia, Lithuania, Malta, the Netherlands,
Norway, Slovenia, Slovakia, and Sweden; and from re-
gional cancer registries for Austria, France, Germany,
Italy, Poland, Portugal, Spain, Switzerland, and the United
Kingdom. To ensure that national populations were
adequately represented in countries where only regional
cancer registries exist, we assessed the geographical
coverage and distribution of these registries.
Five of the 32 countries selected did not have data avail-
able in CI5 Volume X: Greece, Hungary, Liechtenstein,
Luxemburg, and Romania. Because of its very low popula-
tion size, we excluded Lichtenstein from our analysis. For
the remaining four countries, we extrapolated age-specific
average cancer incidence rates from neighboring countries,
or from cancer registries in the same area as the countries
selected. The choice of countries used for extrapolation was
the same as that used for Globocan [9]. Thus, for Greece
data from Bulgaria, Cyprus, and Central Serbia were used;
for Hungary data from Austria, Croatia, Central Serbia,
Slovakia, and Slovenia were used; for Luxemburg data from
French and German cancer registries were used; and for
Romania data from Bulgaria, Slovakia, and one regional
registry in Romania were used. In conclusion, our results
refer to a geographical region of 31 European countries.
The incidence of cancer of the cervix (ICD-10 code
C53), vulva (C51), vagina (C52), anus (C21), penis (C60),
and selected head and neck cancers that are known to
be at least partially related to HPV [6]: oral cavity cancers
(C02-06), nasopharyngeal cancers (C11), oropharyngeal
cancers (C01, C09, C10), hypopharyngeal cancers (C12-
13), unspecified pharyngeal cancers (C14), and laryngeal
cancers (C32) [6] was derived from CI5 Volume X. Based
on these data, we estimated the mean annual number of
new cancers at these sites in 2015 in the 31 selected coun-
tries by extrapolating the sex- and age-specific cancer inci-
dence data [10] to the population of each country, using
2015 Eurostat population data [11]. Calculations were per-
formed as follows:
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where AIR is the age- and sex-specific annual incidence
rate, and population is the age- and sex-specific popula-
tion of a given country. The estimated number of new
cancers at these sites in all the selected countries were
then summed to obtain the overall European burden of
these cancers.
Estimation of the annual number of new cancers
attributable to all HPV types and to 9-valent HPV vaccine
types in Europe
The number of new cancers attributable to all HPV
types and to 9-valent HPV vaccine types (HPV6, 11,
16, 18, 31, 33, 45, 52, and 58) was estimated by
applying the corresponding cancer site-specific HPV
attributable fraction. For cervical cancers, the HPV at-
tributable fraction was considered to be 100%, as it is
generally accepted that HPV infection is necessary for
the development of cervical cancer [12]. However, for
all other cancer sites, the fraction attributable to all
HPV types and to 9-valent HPV vaccine types was
based on the prevalence of oncogenically-active HPV
infections (i.e., detection of HPV DNA and either
mRNA and/or p16 positivity), which was taken from
reference publications based on a large European
multicenter study (Table 1). These publications
contain the most relevant cancer site-specific data pub-
lished to-date [6, 7, 13–16] and covered all our selected
sites. European data on oncogenically-active HPV infec-
tions were not directly available in these publications; they
were obtained from the authors, who are also co-authors
of the present study (LA and SdS). To avoid overestimat-
ing the contribution of individual HPV types due to mul-
tiple infections, the contribution of individual HPV types
to multiple infections was calculated under a weighting at-
tribution, proportional to the prevalence of each individ-
ual HPV type in single infections. We always used
European-specific crude data and the same contribution
estimates were used for both sexes.
Estimation of the annual number of new precancerous
lesions and genital warts cases attributable to all HPV
types and to 9-valent HPV vaccine types in Europe
The methodology used to estimate the annual number
of new precancerous lesions of the cervix, vulva, vagina,
and anus, as well as genital warts was comprehensively
described in our previous work [5]. In the present paper
we updated this estimate, as well as the fraction attributable
to all HPV types and 9-valent HPV vaccine types for the
2015 population [11].
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Table 1 Fraction of cancers attributable to all HPV types and to 9-valent HPV vaccine typesa by cancer site
Cancer site ICD-10 code Fraction attributable
to all HPV types
% [95% CI]b
Fraction attributable to 4-valent
HPV vaccine types
(6/11/16/18) % [95% CI]b





Cervix C53 100c 72.9 [71.0-74.8] 89.1 [87.7-90.4] [13]
Vulva C51 15.9 [13.5-18.4] 84.4 [77.3-90.0] 94.3 [89.1-97.5] [14]
Vagina C52 70.2 [62.2-77.4] 72.6 [63.1-80.9] 87.1 [78.8-92.6] [16]
Anus C21 87.1 [81.0-91.8] 91.5 [85.7-95.6] 94.4 [89.2-97.5] [15]
Penis C60 29.0 [24.7-33.7] 78.9 [70.6-85.9] 90.7 [84.1-95.3] [7]
Oral cavity C02-06 3.7 [2.4-5.6] 90.9 [70.8-98.9] 90.9 [70.8-98.9] [6]
Nasopharynx C11 10.8 [3.0-25.4] 75.0 [19.4-99.4] 75.0 [19.4-99.4] [6]
Oropharynx C01, C09, C10 19.9 [17.2-22.8] 93.8 [88.8-97.0] 97.5 [93.7-99.3] [6]
Hypopharynx C12-13 2.4 [0.3-8.4] 50.0 [1.3-98.7] 100 [15.8-100] [6]
Pharynx C14 25.0 [10.7-44.9] 85.7 [42.1-99.6] 85.7 [42.1-99.6] [6]
Larynx C32 2.4 [1.2-4.1] 66.7 [34.9-90.1] 91.7 [61.5-99.8] [6]
CI confidence interval, HPV human papillomavirus, ICD-10 International Classification of Diseases, 10th Revision, CI confidence interval
aAdjusted for multiple infections; bExcept for cervical cancer, prevalence is based on oncogenically-active HPV infections only (i.e., HPV DNA detection plus either
E6*I mRNA expression or p16 overexpression). cHPV is the necessary cause for cervical cancer [12]
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Results
Estimated annual number of new cancers attributable
to all HPV types and to 9-valent HPV vaccine types in
Europe (Table 2, Additional file 1)
Cervical cancer
The estimated annual number of new cervical cancers in
2015 was 34,939 (95% bound: 32,863-37,032) in the
31selected European countries combined. Applying our
overall HPV attributable fraction of 100%, all of these
cases are believed to be HPV-related. The fraction of
cases attributable to 9-valent HPV vaccine types was
89.1% (95% CI: 87.7-90.4). Accordingly, a total of 31,130
(95% bound: 28,800-33,495) cases were estimated to be
attributable to these types.
Vulvar cancer
The estimated annual number of new vulvar cancers was
9,776 (95% bound: 8,727-10,841). Given an overall HPV
attributable fraction of 15.9% (95% CI: 13.5-18.4) [14],
1,554 (95% bound: 1,135-2,044) cases were estimated to
be attributable to all HPV types. In our reference publi-
cation, the fraction of these cases attributable to 9-valent
HPV vaccine types was estimated at 94.3% (95% CI:
89.1-97.5) [14]. Thus 1,466 (95% bound: 1,008-1,994)
cases were estimated to be attributable to these types.
Vaginal cancer
The estimated annual number of new vaginal cancers
was 2,224 (95% bound: 1,723-2,744). Of these cases,
1,562 (95% bound: 1,058-2,134) were estimated to be
attributable to all HPV types, assuming an overall HPV
attributable fraction of 70.2% (95% CI: 62.2-77.4) [16].
The fraction of these cases attributable to 9-valent HPV
vaccine types in our reference publication was 87.1%
(95% CI: 78.8-92.6). Applying this value, 1,360 (95%
bound: 827–1,980) cases were estimated to be attributable
to these types.
Anal cancer
The estimated annual number of new anal cancers was
4,663 (95% bound: 3,968-5,375) among women and
2,801 (95% bound: 2,260-3,359) among men in Europe.
Given an overall HPV attributable fraction of 87.1%
(95% CI: 81.0-91.8) [15], 4,062 cases (95% bound:
3,203-4,940) in women and 2,440 cases (95% bound:
1,822-3,088) in men were estimated to be attributable
to all HPV types. The fraction of these cases attributable
to 9-valent HPV vaccine types in our reference publication
was 94.4% (95% CI: 89.2-97.5). After applying this value,
3,834 (95% bound: 2,851-4,818) cases in women and 2,303
(95% bound: 1,621-3,012) cases in men were estimated
to be attributable to these types.
Table 2 Estimated mean annual number of new HPV-attributable cancer cases in women and men in Europe
Cancer site New cancers
N, (95% bound)
New cancers attributable
to all HPV types
N, (95% bound)a
New cancers attributable to 9-valent




































































HPV human papillomavirus, N number, CI confidence interval, F female, M male
aExcept for cervical cancer, prevalence is based on oncogenically-active HPV infections only (i.e., HPV DNA detection plus either E6aI mRNA expression or p16
overexpression)
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Penile cancer
The estimated annual number of new penile cancers was
4,231 (95% bound: 3,543-4,937). Assuming an overall
HPV attributable fraction of 29.0% (95% CI: 24.7-33.7)
[7], 1,227 (95% bound: 845–1,697) cases were estimated
to be attributable to all HPV types. Of these cases, the
fraction attributable to 9-valent HPV vaccine types in
our reference publication was 90.7% (95% CI: 84.1-95.3);
thus 1,113 (95% bound: 707–1,619) cases were estimated
to be attributable to these types.
Head and neck cancers
The estimated annual number of new head and neck
cancers was 18,052 (95% bound: 13,977-22,183) among
women and 81,989 (95% bound: 73,563-90,469) among
men. Of these, 1,396 (95% bound: 728–2,592) cancers in
women and 5,834 (95% bound: 3,729-9,735) cancers in
men were estimated to be attributable to all HPV types,
given an overall HPV attributable fraction of 3.7%
(95% CI: 2.4-5.6) in oral cavity cancers, 10.8% (95% CI:
3.0-25.4) in nasopharyngeal cancers, 19.9% (95% CI:
17.2-22.8) in oropharyngeal cancers, 2.4% (95% CI:
0.3-8.4) in hypopharyngeal cancers, 25.0% (95% CI:
10.7-44.9) in pharyngeal cancers, and 2.4% (95% CI:
1.2-4.1) in laryngeal cancers. The fraction attributable
to 9-valent HPV vaccine types in our reference publi-
cation was 90.9% (95% CI: 70.8-98.9), 75.0% (95% CI:
19.4-99.4), 97.5% (95% CI: 93.7-99.3), 100% (95% CI:
15.8-100), 85.7% (95% CI:42.1-99.6) and 91.7% (95% CI:
61.5-99.8) for oral cavity cancers, nasopharyngeal can-
cers, oropharyngeal cancers, hypopharyngeal cancers,
pharyngeal cancers, and laryngeal cancers, respectively.
After applying these values, a total of 1,301 (95% bound:
586–2,574) head and neck cancers cases in women and
5,485 (95% bound: 2,923-9,680) in men were estimated to
be attributable to 9-valent HPV vaccine types. The most
frequent HPV type in head and neck cancers is HPV16,
which is most commonly present as a single-type infec-
tion, but a small proportion of these cancers contain
HPV18, or, even less frequently, HPV31 or 33.
Estimated annual number of new precancerous lesions
attributable to all HPV types and 9-valent HPV vaccine
types in Europe
Cervical intraepithelial neoplasia grade 2 or worse
Based on the age-specific incidence rates, the estimated
annual number of new cervical intraepithelial neoplasia
grade 2 or worse (CIN2+) cases in women in Europe
ranged between 263,227 and 503,010. Of these cases,
82.3% were estimated to be attributable to 9-valent HPV
vaccine types. After applying these values, 216,636 to
413,977 new CIN2+ cases were estimated to be attributable
to these types in 2015.
Vulvar intraepithelial neoplasia grades 2 and 3
Based on the age-specific incidence data, the estimated
annual number of new vulvar intraepithelial neoplasia
grades 2 and 3 (VIN2/3) cases was between 13,997 and
27,773. Of these cases, 86.9% (95% CI: 82.6-90.4) were
estimated to be attributable to all HPV types, with 9-
valent HPV vaccine types accounting for 94.4% (95% CI:
91.0-96.9) of them. Based on these estimates, 12,164 to
24,135 of the VIN2/3 cases were estimated to be attrib-
utable to all HPV types and 11,482 to 22,783 to 9-valent
HPV vaccine types.
Vaginal intraepithelial neoplasia grades 2 and 3
Based on age-specific incidence data, the estimated
annual number of new vaginal intraepithelial neoplasia
grades 2 and 3 (VaIN2/3) cases in women in Europe
ranged between 2,596 and 4,751. Of these cases, 95.8%
(95% CI: 91.8-98.2) are expected to be attributable to all
HPV types, with 9-valent HPV vaccine types accounting
for 77.6% (95% CI: 70.6-83.3) of them. Based on these
estimates, 2,487 to 4,551 cases were expected to be
attributable to all HPV types, and 1,930-3,532 cases to
9-valent HPV vaccine types.
Anal intraepithelial neoplasia grades 2 and 3
Based on the age-standardized rate of 0.58 and 0.43 per
100,000 person-years for anal intraepithelial neoplasia
grades 2 and 3 (AIN2/3) in women and men, respect-
ively [17], 1,549 new AIN2/3 cases were estimated to
occur each year in women and 1,097 cases in men. Of
these cases, 95.3% (95% CI: 84.2-99.4%) are believed to
be attributable to all HPV types [15]. Applying these
values resulted in 1,477 and 1,045 cases attributable to
all HPV types in women and men, respectively, of which
81.5% (95% CI: 66.4-91.9) were attributable to 9-valent
HPV vaccine types, corresponding to 1,203 cases in
women and 852 cases in men (Table 3).
Estimated annual number of new genital warts cases
attributable to HPV in Europe
The estimated annual number of new genital warts cases
ranged between 379,330 and 510,492 in women, and be-
tween 376,608 and 427,720 in men. Assuming that the
low-risk 9-valent HPV vaccine types account for 90% of all
genital warts cases [18], between 341,397 and 459,443 of
these cases in women and between 338,947 and 384,948 of
these cases in men were estimated to be attributable to
these types (Table 4).
Discussion
To our knowledge, this is the first estimation of the an-
nual number of new cancers, precancerous lesions, and
genital warts attributable to 9-valent HPV vaccine types
in women and men in Europe (EMA territory plus
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Switzerland), reflecting the overall burden of disease,
including penile and head and neck cancers. Our esti-
mates demonstrate the high disease burden associated
with 9-valent HPV vaccine types (HPV6, 11, 16, 18, 31,
33, 45, 52, and 58) (Fig. 1). Among the 53,013 (95%
bound: 45,886 to 62,589) new cancers attributable to all
HPV types occurring yearly in Europe, 47,992 (95%
bound: 39,785-58,511) are expected to be attributable to
9-valent HPV vaccine types, i.e., about 90% (see Table 2).
About 81% of these cases (39,091; 95% bound: 34,320 to
44,513) occur in women and 19% (8,901; 95% bound:
5,348 to 14,168) in men. Cervical cancer represents the
highest burden (31,130 cases), followed by head and
neck cancer (6,786 cases), anal cancer (6,137 cases), vul-
var cancer (1,466 cases), vaginal cancer (1,360 cases),
and penile cancer (1,113 cases). HPV-attributable head
and neck cancers constitute a heavy burden in Europe,
particularly in men (1,396 cases in women, 5,834 cases
in men). Overall 75–100% of these are associated with
9-valent HPV vaccine types, with HPV16 being the main
contributor (50–92% attributable to this type specifically,
depending on subsite).
In a previous work we estimated the incremental burden
attributable to the five new vaccine types [5]; the relative
increase in the number of new cancers attributable to
HPV16/18/31/33/45/52/58 compared to HPV16/18 was
19%. In the present work we estimated the burden attrib-
utable to all nine HPV types and based our estimates for
cancers others than cervical cancer on oncogenically-
active fractions only. Also, this is the first estimate of the
burden of penile and head and neck cancers. However, the
additional benefit of the 9-valent vaccine compared to the
quadrivalent or bivalent vaccine would not have essentially
changed the earlier estimate of 19%, as head and neck
cancers are mainly driven by HPV16.
In addition to cancers, 232,103 to 442,347 new precan-
cerous lesions (CIN2+, VIN2/3, VaIN2/3, and AIN2/3)
and 680,344 to 844,391 new genital warts cases (341,397
to 459,443 in women; 338,947 to 384,948 in men) per year
are expected to be attributable to 9-valent HPV vaccine
types. Precancerous lesions of the penis are known to be
largely HPV-related: 89.1% of penile high-grade squamous
intraepithelial lesions were estimated to be HPV-related in
Europe, with 92% of them attributable to 9-valent HPV
vaccine types [7]. However, it was not possible to find a
robust data source to evaluate the incidence of penile
intraepithelial neoplasia in Europe; therefore the bur-
den associated to this disease could not be evaluated.
Similarly, the burden of precancerous lesions of the
head and neck could not be estimated, as no screening
exists. The burden of RRP, a rare but dreadful condition
that is almost exclusively attributable to HPV6 and 11,
is also missing, as available incidence data are too
scarce to be extrapolated to large populations [19, 20].
Strengths and limitations
All data used to evaluate the burden of HPV-attributable
cancers, precancerous lesions, and genital warts were
collected during the most recent period before HPV vac-
cine introduction in Europe. Thus these data reflect the
theoretical burden of these diseases when cervical cancer
screening was the only method for disease prevention;
before any impact of vaccination would be evident.
There are regional differences in the incidence of cervical
cancer that are due predominantly to the combination of
HPV prevalence (that depend on the cultural environment
Table 3 Estimated annual number of new precancerous lesions in women and men in Europe
Precancerous lesion New precancerous lesions (range) New precancerous lesions
attributable to all HPV
types (range)
New precancerous lesions attributable
to 9-valent HPV vaccine types
(6/11/16/18/31/33/45/52/58) (range)
CIN 2+ 263,227 – 503,010 263,227 – 503,010 216,636 – 413,977
VIN 2/3 13,997 – 27,773 12,164 – 24,135 11,482 – 22,783
VaIN 2/3 2,596 – 4,751 2,487 – 4,551 1,930 – 3,532
AIN 2/3 (F) 1,549 1,477 1,203
AIN 2/3 (M) 1,097 1,045 852
Total (both sexes) 282,466 - 538,180 280,399 - 534,218 232,103 - 442,347
HPV human papillomavirus, CIN2+ cervical intraepithelial neoplasia grade 2 or worse, VIN2/3 vulvar intraepithelial neoplasia grades 2 and 3, VaIN2/3 vaginal
intraepithelial neoplasia grades 2 and 3, AIN2/3 anal intraepithelial neoplasia grades 2 and 3, CIN 2+ includes CIN2/3 and AIS, N number, F female, M male
Table 4 Estimated annual number of new genital warts cases in women and men in Europe
N of new annual cases (range) N of new annual cases attributable to HPV6/11 (range)
Women 379,330 – 510,492 341,397 – 459,443
Men 376,608 – 427,720 338,947 – 384,948
Total (both sexes) 755,937 – 938,212 680,344 – 844,391
HPV human papillomavirus, N number
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and related behavioral pattern) and the presence and
effectiveness of population-based screening programs.
Within Europe, the highest rates are observed in Eastern
Europe, followed by Northern Europe, Southern Europe
and Western Europe, where incidence is lowest. World-
wide highest incidence rates are observed in countries with
low ranking of the Human Development Index and lowest
rates are measured in Western Asia, Australia and the
United States [21].
A short-term prediction method was used to estimate
the number of new cancer cases in 2015 from the most
recent data collected from 2003 to 2007. These estimates
presuppose that the incidence rates of the cancers under
study remained stable over time. In the case of increas-
ing incidence, as observed for anal cancers and HPV-
related head and neck cancers over the last few decades
[17, 22–28], this could lead to a slight underestimation
of the expected number of cases. The opposite would be
true in the case of decreasing incidence.
As mentioned above, the CI5 database contains na-
tional cancer incidence rates for 19 European countries.
Eight of the countries included in this report had only
regional incidence rates available, which were extrapo-
lated to the entire country. Although we assessed the
geographical coverage and distribution of these regional
registries, other factors could vary and influence regional
incidence rates. For the remaining four countries no ro-
bust regional or national data were available. We thus
extrapolated the mean incidence data from surrounding
cancer registries to these countries, but we had no
means to check the robustness of this method. Therefore
the results for those countries should be interpreted with
particular caution.
Our calculations of HPV-attributable cancers other
than cervical cancer were based on data provided by a
large European multicenter study [6, 7, 13–16], which
contains the most relevant cancer site-specific data pub-
lished to-date and that provided estimates adjusted for
multiple infections, in order not to overestimate the
weight of individual HPV types.
Moreover, for cancers other than cervical cancer, the
HPV attributable fractions were based on oncogenically-
active HPV infections only (i.e., detection of HPV DNA
and either mRNA and/or p16 positivity, which are
markers of biological activity). Indeed, non-cervical can-
cers may occur for reasons other than HPV infection;
the mere presence of HPV DNA is insufficient to prove
causation, as the infection may be transient and not
related to the carcinogenic process. This may be particu-
larly true for head and neck cancers, for which tobacco
and alcohol are known to be major risk factors. These
additional criteria were implemented mainly to avoid
overestimating the HPV attributable fraction in non-
cervical cancers. Still, we cannot completely rule out the
possibility that mRNA or protein was degraded in the
paraffin-embedded samples in our reference publication,
which could trigger false negativity for biological HPV
activity. To evaluate this, we looked at the proportion of
oncogenically-active HPV-positive samples with those
that were HPV DNA-positive only, and compared it with
the proportion observed in a recent meta-analysis on the
same topic for head and neck cancers [29]. These pro-
portions were consistent for oropharyngeal cancers
(~87% of oncogenically-active HPV-positive cancers in
the meta-analysis vs 91% in our reference study). How-
ever, this proportion was more heterogeneous for other
head and neck cancers: 86% of HPV-related laryngeal
cancers were considered to be attributable to HPV based
on p16 detection, but this number decreased to 39%
when based on mRNA in the meta-analysis (vs 61% in
the study we used as reference); 28% of HPV-positive
oral cavity cancers were considered to be attributable to
Fig. 1 Overall burden of diseases attributable to the 9-valent HPV vaccine types in men and women in Europe. CIN2+: cervical intraepithelial neoplasia
grade 2 or worse; VIN2/3: vulvar intraepithelial neoplasia grades 2 and 3; VaIN2/3: vaginal intraepithelial neoplasia grades 2 and 3; AIN2/3: anal
intraepithelial neoplasia grades 2 and 3
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HPV based on p16 detection, but 67% when based on
mRNA in the meta-analysis (vs 59% in the reference
study). It should also be noted that overall HPV DNA
prevalence by subsite in the meta-analysis was higher
(41.4% for oropharyngeal cancers, 20.9% for laryngeal
cancers, and 17.5 for oral cavity cancers in Europe) than
that observed in our reference publication (22.3% for
oropharyngeal cancers, 4.8% for laryngeal cancers, and
7.8% for oral cavity cancers). Our estimated annual
number of new head and neck cancers attributable to
HPV should thus be considered a conservative estimate.
Some regional differences were observed in the preva-
lence of HPV in head and neck cancers in Europe. For
example, the oncogenically-active HPV attributable frac-
tion in oropharyngeal cancer ranged from 9.4% in
Southern Europe to 50% in Northern Europe [6]. How-
ever, for the purpose of our study it was not possible to
apply country-specific data, as the available data did not
cover all European countries and small sample sizes
would not have provided robust results.
Sex-specific data for HPV prevalence in anal cancer
and head and neck cancers were available, but were not
used. No sex-specific differences in HPV prevalence
were seen in anal cancer (oncogenically-active HPV
prevalence was 88.2 (95% CI: 76.1-95.6) in men vs 87.2
(95% CI: 79.4-92.8) in women). Even if some differences
in HPV attributable fractions by sex were high in some
head and neck subsites, particularly in oropharyngeal
cancers (16.9% (95% CI: 14.1-20.0) in men vs 40.2%
(95% CI: 31.4-49.4) in women), this was not confirmed
by a recent literature review on the topic [30]. According
to the analysis of Combes et al., there are regional differ-
ences in the sex-specific HPV prevalence of oropharyngeal
cancers worldwide and within Europe (male:female HPV
prevalence ratio <1 in France, Germany, Italy, and the
Czech Republic; male:female ratio ≥1 in the Netherlands,
Norway, the United Kingdom, and Sweden). Still, when
considering Europe as a whole, and based on 27 studies
conducted in 9 countries of the European Union with less
than 200 subjects each, the male:female ratio for HPV
prevalence in oropharyngeal cancers was 1.0 (0.9-1.1), and
the estimated HPV prevalence in oropharyngeal cancers
was 40.3 in males and 41.2 in females. In addition, that
paper suggested that smoking and heavy drinking may
either enhance the carcinogenic effect of HPV or hamper
the accurate attribution of oropharyngeal cancers to HPV
in men who have both the infection and exhibit the two
lifestyle risk factors related to this disease. The sex-
specific differences in HPV prevalence in oropharyngeal
cancer are mainly a consequence of the vast international
variation in male smoking habits. According to these
results, and as the difference in the male:female ratio ob-
served in our reference publication may be due to chance
(regional representativity of participating countries), we
finally decided to use a single HPV attributable fraction
for oropharyngeal cancer for males and females.
Moreover, a declining incidence of HPV-negative oro-
pharyngeal squamous cell carcinoma is currently being
observed in the United States that parallels with declines
in smoking. In contrast, increasing incidence of HPV-
positive OPSCCs perhaps arises from increased oral sex
and oral HPV exposure over calendar time. Indeed, preva-
lence of genital herpes simplex virus 1 (HSV1), HSV2, and
genital warts have increased among recent birth cohorts
in the United States, accepted surrogates for oral sex, risky
sexual behavior, and HPV exposure, respectively. The pre-
dominant rise in OPSCC incidence among the young is
also consistent with changing HPV exposure among re-
cent birth cohorts. However, the reasons for pronounced
increases among men remain unexplained [31]. Therefore
it is critical to understand if there is an underlying epi-
demic of HPV-positive head and neck cancers related to
changes in sexual habits, because this could change all our
forecasts of the HPV- related epidemiology of head and
neck cancer.
A further limitation is represented by the fact that only
one-digit ICD codes are available in the CI5 database,
meaning that some of the head and neck cancer subsites
could not be correctly assigned. For example C.5.1 (soft
palate), C.5.2 (uvula) were classified as oral cancers and
C.14.2 (Waldeyers ring) as pharyngeal cancers, but ana-
tomically they all belong to the oropharynx.
The method used to calculate the estimated annual
number of new precancerous lesions also has some limi-
tations that were described in our previous estimation of
HPV-related burden of disease [5].
To our knowledge, the data that we used for our esti-
mation of cancers, precancerous lesions, and genital
warts are the most robust data available in Europe to-
date. However, the results of this evaluation have to be
considered with caution, as several extrapolations and
assumptions were used. Future studies are necessary;
mainly to further evaluate the HPV attributable fraction
of head and neck cancers and the real burden of precan-
cerous lesions of the vulva, vagina, and anus, for which
no systematic screening is performed. Additionally, inci-
dence data are completely lacking for precancerous
lesions of the penis and in the head and neck area and
are very scarce for RRP.
Conclusions
The burden of cancers attributable to 9-valent HPV vac-
cine types in Europe is substantial, both in women and
men. Overall, 53,013 (95% bound: 48,160-67,171) HPV-
attributable cancers were estimated to occur every year
in Europe, of which more than 90%, (47,992 (95%
bound: 39,785-58,511)) were estimated to be attributable
to 9-valent HPV vaccine HPV types. When considering
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head and neck cancers in addition to anogenital cancers,
about 19% of all HPV-attributable cancers are expected
to occur in men, and most of these cancers are attribut-
able to 9-valent HPV vaccine types. In addition to cancers,
232,103 to 442,347 new cases of precancerous lesions
(CIN2/3, adenocarcinoma in situ, VIN2/3, VaIN2/3, and
AIN2/3) and 680,344 to 844,391 new genital warts cases
(341,397 to 459,443 in women, 338,947 to 384,948 in
men) are expected to be attributable to the 9-valent HPV
vaccine types each year. This data demonstrates the
important preventive potential of the new 9-valent HPV
vaccine in Europe.
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